2024
Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities
Feemster K, Buchwald U, Banniettis N, Joyce J, Velentgas P, Chapman T, Yildirim I. Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities. Open Forum Infectious Diseases 2024, 11: ofae220. PMID: 38770212, PMCID: PMC11103622, DOI: 10.1093/ofid/ofae220.Peer-Reviewed Original Research
2023
Influenza Vaccine Effectiveness Pre-pandemic Among Adults Hospitalized With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease and Older Adults
Tippett A, Ess G, Hussaini L, Reese O, Salazar L, Kelly M, Taylor M, Ciric C, Keane A, Cheng A, Gibson T, Li W, Hsiao H, Bristow L, Hellmeister K, Al-Husein Z, Hubler R, Begier E, Liu Q, Gessner B, Swerdlow D, Kamidani S, Kao C, Yildirim I, Rouphael N, Rostad C, Anderson E. Influenza Vaccine Effectiveness Pre-pandemic Among Adults Hospitalized With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease and Older Adults. Clinical Infectious Diseases 2023, 78: 1065-1072. PMID: 37946601, DOI: 10.1093/cid/ciad679.Peer-Reviewed Original ResearchInfluenza-related hospitalizationsAcute respiratory illnessCongestive heart failureInfluenza vaccination historyInfluenza vaccine effectivenessVaccine effectivenessYears of ageCOPD exacerbationsHeart failureVaccination historyChronic obstructive pulmonary disease exacerbationsTest-negative case-control studyObstructive pulmonary disease exacerbationsChronic obstructive pulmonary diseaseAdjusted vaccine effectivenessHigh-risk comorbiditiesPulmonary disease exacerbationsObstructive pulmonary diseaseEligible study populationMultivariable logistic regressionConfidence intervalsCase-control studyRace/ethnicityVaccine registryDisease exacerbation
2022
The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants
Kim D, Keskinocak P, Pekgün P, Yildirim İ. The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants. Scientific Reports 2022, 12: 7493. PMID: 35523832, PMCID: PMC9075929, DOI: 10.1038/s41598-022-11060-8.Peer-Reviewed Original ResearchConceptsOverall public health impactInfection attack rateCOVID-19 vaccineSARS-CoV-2Public health impactVaccine effectivenessAdverse outcomesMultiple vaccinesInitial efficacySuccessful immunization strategyImmunization strategiesVaccineLow-income countriesAttack rateEfficacyCOVID-19COVID-19 pandemicHealth impactsInfection spreadRecovered-deceased [SI(Q/F)RD] modelEfficacy levelsPandemicHospitalizationVaccinationVariants
2021
A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children
Yildirim I, Kao CM, Tippett A, Suntarattiwong P, Munye M, Yi J, Elmontser M, Quincer E, Focht C, Watson N, Bilen H, Baker JM, Lopman B, Hogenesch E, Rostad CA, Anderson EJ. A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children. Clinical Infectious Diseases 2021, 73: 1759-1767. PMID: 34410341, PMCID: PMC8599178, DOI: 10.1093/cid/ciab709.Peer-Reviewed Original ResearchConceptsInfluenza vaccine effectivenessInfluenza-positive casesInfluenza-related hospitalizationsVaccine effectivenessInfluenza seasonOdds ratioInfluenza ALaboratory-confirmed influenza-related hospitalizationsTest-negative case-control study designAdjusted vaccine effectivenessInfluenza-negative controlsTest-negative controlsCase-control study designHospitalization of childrenTest-negative casesConfidence intervalsNon-Hispanic blacksLogistic regression modelsPreventing HospitalizationInfluenza vaccinationInfluenza burdenMedian ageInfluenza B.Influenza infectionPediatric hospitalizations
2020
Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012‐2017
Kao CM, Lai K, McAteer JM, Elmontser M, Quincer EM, Yee MEM, Tippet A, Jerris RC, Lane PA, Anderson EJ, Bakshi N, Yildirim I. Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012‐2017. Pediatric Blood & Cancer 2020, 67: e28358. PMID: 32469138, PMCID: PMC8221251, DOI: 10.1002/pbc.28358.Peer-Reviewed Original ResearchConceptsInfluenza vaccine effectivenessSickle cell diseaseVaccine effectivenessYears of ageInfluenza infectionOdds ratioCell diseaseLaboratory-confirmed influenza infectionSeasonal influenza vaccine effectivenessTest-negative case-control study designAdjusted vaccine effectivenessAdjusted VE estimatesInfluenza-positive casesOverall vaccine effectivenessAcute chest syndromeBurden of influenzaPatients 6 monthsMulticenter prospective studyTest-negative controlsAnnual influenza vaccineCase-control study designConfidence intervalsLogistic regression modelsChest syndromeInfluenza seasonCharacteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
Lapidot R, Shea KM, Yildirim I, Cabral HJ, Pelton SI, Health T. Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts. Pathogens 2020, 9: 396. PMID: 32455770, PMCID: PMC7281000, DOI: 10.3390/pathogens9050396.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineIPD casesIncidence rate ratiosIPD incidencePCV-13Disease characteristicsSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceImpact of PCV13Presence of comorbiditiesInvasive pneumococcal diseasePneumococcal disease incidenceUniversal childhood immunizationWaning of immunityPassive surveillance systemPCV13 dosePCV13 introductionVaccine effectivenessConjugate vaccineMassachusetts childrenPneumococcal diseaseClinical syndromeChildhood immunizationIncidence ratePCV13